Cytodyn Inc (CYDY)

[Chuckles759]

Good questions....and if I'm limited to these and can't offer a C), D), etc...

I'd go with B) and the reason why is that if one indication with a partnership could bounce to $3, and I'll choose LH, then a successfully funded trial paid for by the partner would greatly increase the likelihood of an EUA that would hopefully lead to a BLA. Now, granted that the partnership would need to be with a solid BP player that has deep pockets to get a trial done quickly and effectively. LH is real, it is now, and it has everyone's attention. It doesn't look like LH will be "cured" and it might require LL maintenance dosage for weeks if not months to resolve some patients issues. The recurring need will be for at least a couple of years at a fairly high number of patients - it's somewhere around 10% of COVID sufferers...and how many millions of them globally? Revenue and share price increase/stability will allow more funded trials/research that can attract more partners for other indications. Plus, having an approved drug would allow off-label use by smart physicians in ever expanding indications.

Sort of like the camel getting its nose under the edge of the tent.